-
Tehran receives US plan to end Mideast war, as Iran fires at US carrier
-
Aviation, tourism, agriculture... the economic sectors hit by the war
-
Iran fires at US carrier as backchannel diplomacy aims to end war
-
Salah's long goodbye brings curtain down on golden era for Liverpool
-
Monaco: city of vice and a few virtues
-
AI making cyber attacks costlier and more effective: Munich Re
-
Defying Israeli bombs, Lebanese hold out in southern city of Tyre
-
War-linked power crunch pushes Sri Lanka to four-day week
-
Hungary says will phase out gas deliveries to Ukraine
-
Oil prices tumble, stocks rally on Mideast peace hopes
-
Maybach: Between Glory and a Turning Point
-
German business morale falls as war puts recovery on ice: survey
-
Labubu maker Pop Mart's shares fall 23% despite surging earnings
-
ECB won't be 'paralysed' in face of energy shock: Lagarde
-
Iran hits targets across Middle East after Trump signals talks progress
-
McEvoy says best is to come after breaking long-standing swim record
-
Goat vs gecko: A tiny Caribbean island faces wildlife showdown
-
Japan PM asks IEA chief to prepare additional 'coordinated release' of oil
-
Hungary's hard-pressed LGBTQ people say Orban exit is only half battle
-
Belarus leader visits North Korea for first time
-
'No heavier burden': the decades-long search for Kosovo war missing
-
Exotic pet trade thrives in China despite welfare concerns
-
Iran fires missile salvo after Trump signals progress in talks
-
BTS concert drew 18.4 million viewers, says Netflix
-
OSCE's 'chaotic' Ukraine evacuation put staff at risk: leaked report
-
Top WTO official sounds fertiliser warning over Middle East war
-
France and Brazil weigh up World Cup prospects in glamour friendly
-
Italy hoping to end World Cup pain as play-offs loom
-
Dirty diapers born again in Japan recycling breakthrough
-
Verstappen's Japan GP win streak under threat as Mercedes dominate
-
Crude tumbles, stocks rally on hopes for Iran war de-escalation
-
Gauff outlasts Bencic to reach Miami semi-finals
-
'Hero' Australian dog who saved 100 koalas retires
-
Underdogs chase World Cup berths in Mexico playoff tournament
-
Pope heads to tiny Catholic Monaco
-
Meet the four astronauts set to voyage around the Moon
-
Artemis 2 Moon mission: a primer
-
It's go time: historic Moon mission set for lift-off
-
Denmark's PM Mette Frederiksen, tenacious and tough on migration
-
OpenAI kills Sora video app in pivot toward business tools
-
Danish PM's left-wing bloc wins election, but no majority
-
Phomemo Highlights the M08F Plus Wireless Tattoo Stencil Printer for Spring 2026 Equipment Selection
-
The SMX Opportunity: When Virgin and Recycled Plastic Are Close to Even
-
ASMALLWORLD Introduces New Marriott Bonvoy(R) Benefit for Members
-
Medical Care Technologies (OTC:MDCE) Launches National iHeartRadio Campaign to Accelerate Snapshot Recipes Growth and User Adoption
-
Telestream Unlocks Adobe-Centric Media Pipeline and Streamlined Workflow Automation
-
42WEST's 2026 SXSW Festival Slate Delivered Marquee Talent and a Standout Film Slate Featuring a Company-Record 16 World Premiere Titles and Three Audience Award-Winners
-
Federato Appoints Tim Mossing as Chief Customer Officer to Drive AI-Native Insurance Transformations
-
Dispatch Launches Driver Score to Elevate Delivery Professionals and Power Smarter Last-Mile Logistics
-
The GIST Doubles Revenue Amid Rising Demand for Equal Sports Coverage
New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning
NEW YORK, NY / ACCESS Newswire / March 25, 2026 / New to The Street, a premier financial media platform known for its national television distribution and integrated investor engagement strategy, today announced a strategic 12-part media partnership with IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage biotechnology company leveraging artificial intelligence to develop treatments for Alzheimer's disease and metabolic disorders.
The multi-faceted campaign is designed to elevate IGC Pharma's visibility across institutional and retail investor audiences through a coordinated media strategy that includes long-form television interviews, national TV commercial distribution, high-impact outdoor billboard placements, and curated accredited investor events in key financial markets.
Through this initiative, IGC Pharma will be featured across New to The Street's sponsored programming on Fox Business and Bloomberg Television, alongside amplification to a combined digital audience exceeding 4.45 million YouTube subscribers. The campaign will also include dominant outdoor placements in Times Square and the New York City Financial District, as well as earned media distribution across major U.S. broadcast affiliates.
"This partnership represents a strategic step forward in expanding our visibility within the global investment community," said Ram Mukunda, CEO of IGC Pharma. "New to The Street's unmatched ability to combine television, digital distribution, and outdoor media provides us with a powerful platform to communicate our clinical progress, including our Phase 2 CALMA trial, and to position IGC Pharma at the forefront of AI-driven biopharmaceutical innovation."
"We are proud to launch this 12-part series with IGC Pharma at a time when Alzheimer's continues to impact millions of families across the United States and around the world," said Vince Caruso, co-founder and CEO of New to The Street. "This is about more than visibility - it's about bringing forward companies that are working on real solutions. IGC Pharma is advancing meaningful progress in an area of critical need, and through our platform, we aim to elevate their story to the global investment community while offering a sense of hope and potential comfort to those affected by this devastating disease."
New to The Street's integrated platform is engineered to align media exposure with capital markets objectives - driving narrative control, investor engagement, and long-term brand equity for emerging and growth-stage public companies.
About New to The Street
New to The Street is one of the longest-running U.S. and international sponsored television brands, broadcasting weekly as sponsored programming on Fox Business and Bloomberg Television. The platform delivers long-form interviews with innovative public and private companies, combining national TV exposure with digital, social, and outdoor media amplification.
With over 4.45 million YouTube subscribers and one of the most comprehensive media distribution ecosystems in the financial space, New to The Street integrates television broadcasting, earned media placements across ABC, NBC, and CBS affiliates, and dominant billboard visibility throughout Times Square and the NYC Financial District. The platform also provides direct access to accredited investors through curated in-person and virtual events, creating a full-cycle investor awareness and engagement solution.
About IGC Pharma
IGC Pharma, Inc. (NYSE American:IGC) is a clinical-stage biotechnology company leveraging artificial intelligence to develop innovative treatments for Alzheimer's disease and metabolic disorders.
The Company's lead therapeutic candidate, IGC-AD1, is currently in a Phase 2 clinical trial (CALMA) targeting agitation in Alzheimer's dementia. Its pipeline also includes TGR-63, focused on amyloid plaque reduction, along with additional early-stage programs addressing neurodegeneration, tau pathology, and metabolic dysfunction.
By integrating AI into drug discovery, clinical trial design, and patient targeting, IGC Pharma is accelerating development timelines and advancing a portfolio of therapies aimed at addressing significant unmet medical needs. The Company maintains a robust patent portfolio supporting its innovation-driven approach.
Media Contact
Monica Brennan
New to The Street
[email protected]
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of applicable securities laws. These statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause actual results to differ materially. Investors are encouraged to review IGC Pharma's filings with the U.S. Securities and Exchange Commission for additional information regarding these risks.
SOURCE: New to The Street
View the original press release on ACCESS Newswire
Ch.Kahalev--AMWN